Skip to main content

Table 1 Demographic and clinical characteristics of UC patients

From: Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience

Characteristics All patients n = 33
Sex (men/women), n (%) 20 (60.6)/13 (39.4)
Age (years)* 43.2 ± 17.4
Disease duration (years)* 7.0 ± 5.7
Modified Truelove and Witts severity index* 9.4 ± 3.2
Mayo score (endoscopy)* 2.8 ± 0.4
Extent of disease  
  Left-side type, n (%) 13 (39.4)
  Extensive colitis, n (%) 20 (60.6)
Concomitant medications  
  5-ASA formulation, n (%) 29 (87.9)
  Corcicosteroids, n (%) 11 (33.3)
  Azathioprine/Mercaptopurine, n (%) 16 (48.5)
  Tacrolimus, n (%) 13 (39.4)
Cytomegalovirus, n (%) 11 (33.3)
  1. IFX: infliximab, 5-ASA: 5-aminosalicylic acid.
  2. Results reported as number (%) of patients or as *mean ± standard deviation.